The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their ...

Merck has received approval from the Food and Drug Administration for Welireg, its oral inhibitor for patients with certain rare types of neuroendocrine tumors. The company said Wednesday the ...

Merck (MRK) stock in focus as the FDA approves its anticancer agent Welireg for two rare neuroendocrine tumors, expanding its ...

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, ...

One particular island in Japan could hold the secret diet that has been shown to improve longevity and reduce the risk of heart disease. The prefecture of Okinawa is classified as one of the world ...

(Reuters) -Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental drug to treat a life-threatening kidney disease. Under the ...

A recent study found that a daily exposure to phthalates, that is commonly used in making household plastic items, is linked to 3.5 lakh, or 13 per cent, deaths in the world due to heart disease ...

Children with low vitamin D levels face a greater risk of early heart disease, according to a decades-long Finnish study. Could early supplementation shift the tide on cardiovascular prevention?

the company’s blockbuster cancer drug. The plant marks Merck’s first in-house manufacturing site in the U.S. to make Keytruda, and will ensure American patients get the drug made domestically.

Still, sales of its diabetes and heart disease drug Farxiga were nearly 6% higher than expected, while revenue from its newer cancer medicine Enhertu was also ahead. The British drugmaker ...